((自动化翻译由路透提供，请见免责声明 ))
12月20日 - ** 诺和诺德公司（Novo Nordisk）的 下一代肥胖症实验药物在后期试验中的减重效果低于预期，一些减肥药开发商的股票在盘前上涨
** 诺和诺德称其药物CagriSema帮助超重患者减轻了22.7%的体重 (link)，低于其25%的预期。 (link)
** Viking Therapeutics 股价在收盘前上涨11.5%，Structure Therapeutics 上涨7.1%，Altimmune 上涨2.2%，Amgen 上涨5.5%。
** 诺和诺德在美国上市的股票下跌 22.4%，而竞争对手礼来 上涨 10
** 投资者和分析师热切期待着这一数据，以检验诺和诺德是否拥有强大的药物管线，在竞争激烈的抗肥胖症市场上紧随Wegovy之后。
** 礼来公司的肥胖症药物（在美国以 Zepbound 出售）在临床试验中平均减轻了近 23% 的体重
** 截至收盘，AMGN下跌9.3%，GPCR下跌26.5%，ALT下跌27.3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.